Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.30)
# 305
Out of 4,842 analysts
82
Total ratings
53.45%
Success rate
17.02%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $29.04 | +89.39% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $26.93 | +18.83% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $123.64 | +49.63% | 2 | Apr 24, 2025 | |
| SMMT Summit Therapeutics | Initiates: Outperform | $30 | $26.21 | +14.46% | 1 | Mar 12, 2025 | |
| SWTX SpringWorks Therapeutics | Maintains: Outperform | $60 → $65 | $46.68 | +39.25% | 2 | Feb 12, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $33.37 | +49.84% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $14.57 | +243.17% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $100.25 | +24.69% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $58.55 | +79.33% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $605.39 | +94.09% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $63.68 | +33.48% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $35.04 | +151.14% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $132.75 | +107.91% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $2.27 | +1,441.85% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,520 → $780 | $4.97 | +15,594.16% | 5 | Feb 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $283.54 | -18.18% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $66.04 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $111.11 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $30.26 | -30.60% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $3.38 | +580.47% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $9.75 | +2,464.10% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $0.66 | +1,415.61% | 1 | Feb 14, 2018 |
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $29.04
Upside: +89.39%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $26.93
Upside: +18.83%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $123.64
Upside: +49.63%
Summit Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $30
Current: $26.21
Upside: +14.46%
SpringWorks Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $46.68
Upside: +39.25%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $33.37
Upside: +49.84%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $14.57
Upside: +243.17%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $100.25
Upside: +24.69%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $58.55
Upside: +79.33%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $605.39
Upside: +94.09%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $63.68
Upside: +33.48%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $35.04
Upside: +151.14%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $132.75
Upside: +107.91%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $2.27
Upside: +1,441.85%
Feb 17, 2021
Downgrades: Neutral
Price Target: $1,520 → $780
Current: $4.97
Upside: +15,594.16%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $283.54
Upside: -18.18%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $66.04
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $111.11
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $30.26
Upside: -30.60%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $3.38
Upside: +580.47%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $9.75
Upside: +2,464.10%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $0.66
Upside: +1,415.61%